GenVec in brief
GenVec is an unlisted company in the Biotechnology industry, based in Gaithersburg, USA. In the year to December 2016 it had sales of $1 M and a net loss of $6 M. It employs about 15 people.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About GenVec
GenVec, Inc. is a clinical-stage biopharmaceutical company with an entrepreneurial focus on leveraging its proprietary AdenoVerse™ gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines. We are pioneers in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based medicine. Our lead product candidate, CGF166, is licensed to Novartis Institutes for BioMedical Research, Inc. and is currently in a Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. In addition to our internal and partnered pipeline, we also focus on opportunities to license our proprietary technology platform, including vectors and production cell lines, to potential collaborators in the biopharmaceutical industry for the development and manufacture of therapeutics and vaccines.
From the company's annual report filed with the US SEC: read the report
GenVec timeline
- 1998
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
Events of GenVec from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about GenVec
- Acquisitions and changes
- Taken over: the company reported a change in control and the delisting of its shares to the SEC on 16 June 2017 (Form 8-K).
Market cap history
Not enough history yet.
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -1135.3%
- Operating margin
- -1415.7%
- Return on equity
- -123.2%
- Liabilities / assets
- 38.9%
- Revenue growth
- -42.0%
- R&D / revenue
- 490.2%
- Revenue per employee
- $34 K
- Profit per employee
- $-386 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2016 | $1M | -42.0% | $-7M | $-6M | -1135.3% |
| Dec 2015 | $1M | -85.4% | $-7M | $-7M | -743.2% |
| Dec 2014 | $6M | +64.1% | $-3M | $-3M | -41.7% |
| Dec 2013 | $4M | -60.6% | $-10M | $-10M | -272.3% |
| Dec 2012 | $9M | -47.3% | $-14M | $-14M | -150.4% |
| Dec 2011 | $18M | +7.7% | $-7M | $-7M | -41.9% |
| Dec 2010 | $16M | +18.8% | $-13M | $-12M | -74.5% |
| Dec 2009 | $14M | — | $-18M | $-18M | -132.5% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2016 | $-6M | $0M | $-6M | $-2.78 | — |
| Dec 2015 | $-6M | $0M | $-6M | $-3.90 | — |
| Dec 2014 | $-2M | $0M | $-2M | $-0.16 | — |
| Dec 2013 | $-9M | $0M | $-10M | $-0.77 | — |
| Dec 2012 | $-11M | $0M | $-11M | $-1.09 | — |
| Dec 2011 | $-8M | $0M | $-9M | $-0.58 | — |
| Dec 2010 | $-11M | $0M | $-11M | $-0.97 | — |
| Dec 2009 | $-17M | $0M | $-17M | $-1.89 | — |
SEC filings
- Jun 16, 20178-KCurrent reportAcquisition or disposal completed · Listing notice · Change in control · Directors or officers changed · Bylaws amended
- Jun 15, 20178-KCurrent reportShareholder vote
- May 17, 20178-KCurrent reportListing notice
- May 10, 201710-QQuarterly report · period to Mar 2017
- Mar 6, 201710-KAnnual report · period to Dec 2016
- Jan 24, 20178-KCurrent reportMaterial agreement · Other events
- Dec 16, 20168-KCurrent reportOther events
- Dec 1, 20168-KCurrent reportBylaws amended · Other events
- Nov 16, 20168-KCurrent reportOther events
- Nov 4, 201610-QQuarterly report · period to Sep 2016
- Nov 4, 20168-KCurrent reportResults of operations
- Oct 24, 20168-KCurrent reportShareholder vote · Regulation FD disclosure
Official filings of GenVec with the US Securities and Exchange Commission.
Annual results
- Revenue
- $1 M
- Operating income
- $-7 M
- Net income
- $-6 M
For year ending December-2016 · source: SEC filing
Balance sheet
- Total assets
- $8 M
- Total liabilities
- $3 M
- Total equity
- $5 M
As of December-2016
Insider trading at GenVec#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Marc R. SchneebaumDirector | Option exercise | +1,500 | $3.800 | $6 K | 9,050 | Form 4 |
| filed | Douglas E. BroughChief Scientific Officer | Option exercise | +13,000 | $5.600 | $73 K | 26,668 | Form 4 |
| filed | Douglas J. SwirskyPresident and CEO, Director | Option exercise | +25,000 | $5.600 | $140 K | 50,250 | Form 4 |
| filed | James Vincent LambertVP, Accounting & Finance | Option exercise | +4,000 | $5.600 | $22 K | 5,981 | Form 4 |
| filed | Bryan T. ButmanSenior Vice President | Option exercise | +6,000 | $5.600 | $34 K | 14,138 | Form 4 |
| filed | Willam N. KelleyDirector | Option exercise | +1,500 | $3.800 | $6 K | 9,050 | Form 4 |
| filed | Quinterol J. MalletteDirector | Option exercise | +1,500 | $3.800 | $6 K | 1,500 | Form 4 |
| filed | Stefan LorenDirector | Option exercise | +1,500 | $3.800 | $6 K | 2,000 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
GenVec scorecard#
Passes 2 of the 8 checks that could be worked out: strongest in growth (1 of 3), weakest in profitability (0 of 3). Fiscal year 2016.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth1 of 3
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-2.78 vs -3.90Diluted EPS -2.78 in fiscal 2016 against -3.90 the year before (report's currency).
- ✓Net income higher than five years earlier-$6 M-$6 M in fiscal 2016 against -$7 M in 2011.
- ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2016.
Profitability0 of 3
- ✗Profitable in the newest year-$6 MNet income -$6 M in fiscal 2016.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2016.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-93.5%-93.5% in fiscal 2016.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities4.0×Current ratio 4.03 at the end of fiscal 2016.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2016.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
GenVec: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2016to Dec 31, 2016 | FY 2015to Dec 31, 2015 | FY 2014to Dec 31, 2014 | FY 2013to Dec 31, 2013 | FY 2012to Dec 31, 2012 | FY 2011to Dec 31, 2011 | FY 2010to Dec 31, 2010 | FY 2009to Dec 31, 2009 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 0.5−42.3%100% | 0.9−85.4%100% | 6.0+64.1%100% | 3.7−60.6%100% | 9.4−47.3%100% | 18+7.8%100% | 16+18.8%100% | 14—100% | |
| Research and development | 2.5−2.0%489% | 2.6+12.7%288% | 2.3−58.8%37.5% | 5.5−61.7%149% | 14−17.6%153% | 17−16.8%98.2% | 21−15.2%127% | 25—178% | |
| General and administrative | 5.2+6.7%1023% | 4.9−22.4%554% | 6.3−25.6%105% | 8.5−6.8%230% | 9.1+16.5%97.3% | 7.8−4.2%44.0% | 8.2+13.6%49.5% | 7.2—51.8% | |
| Operating expenses | 7.7+3.7%1512% | 7.5−13.1%842% | 8.6−38.6%142% | 14−40.4%380% | 23−7.0%251% | 25−13.3%142% | 29−8.7%177% | 32—230% | |
| Operating income | −7.2—−1412% | −6.6—−742% | −2.5—−42.0% | −10—−280% | −14—−151% | −7.5—−42.2% | −13—−76.6% | −18—−130% | |
| Other non-operating income (expense) | 1.4+6391%279% | 0.0—2.5% | — | — | 0.0+2.4%0.4% | 0.0−88.2%0.2% | 0.3—2.1% | −0.4—−2.6% | |
| Net income attributable to shareholders | −5.8—−1132% | −6.5—−740% | −2.5—−41.6% | −10—−272% | −14—−150% | −7.4—−41.9% | −12—−74.5% | −18—−133% | |
| Earnings per share, basic | -2.78—— | -3.90r-0.39—— | -0.16—— | -0.77—— | -1.09—— | -0.58—— | -0.97—— | -1.89—— | |
| Earnings per share, diluted | -2.78—— | -3.90r-0.39—— | -0.16—— | -0.77—— | -1.09—— | -0.58—— | -0.97—— | -1.89—— | |
| Shares, weighted average (diluted) | 0.0+24.0%— | 0.0r0.0−89.4%— | 0.0r16−99.9%— | 13—— | — | — | — | — | |
| Balance sheet | |||||||||
| Cash and cash equivalents | 3.7−47.7%47.6% | 7.0−12.0%74.1% | 8.0+51.8%51.0% | 5.2+26.5%72.4% | 4.2+0.9%23.8% | 4.1−88.2%13.6% | 35+222%88.8% | 11—— | |
| Short-term investments | — | — | — | — | 11−50.3%63.7% | 22+13193%74.1% | 0.2—0.4% | — | |
| Receivables | 0.0−86.7%0.3% | 0.2−48.9%1.8% | 0.3+61.7%2.1% | 0.2−78.8%2.8% | 0.9−64.6%5.4% | 2.7r2.4−16.7%8.9% | 3.2—8.1% | — | |
| Other current assets | 0.3+10.6%3.5% | 0.2+11.9%2.6% | 0.2−35.0%1.4% | 0.3+49.1%4.6% | 0.2−1.7%1.3% | 0.2−5.0%0.8% | 0.2—0.6% | — | |
| Current assets | 7.5−17.9%96.8% | 9.1−40.4%96.0% | 15+129%97.6% | 6.6−59.6%91.6% | 16−44.0%94.3% | 29r29−24.0%97.3% | 39—97.9% | — | |
| Property, plant and equipment | 0.2−31.5%2.5% | 0.3+1.1%2.9% | 0.3−46.3%1.8% | 0.5−36.1%7.1% | 0.8+16.3%4.6% | 0.7−6.9%2.3% | 0.7—1.9% | — | |
| Total assets | 7.7−18.6%100% | 9.5−39.4%100% | 16+115%100% | 7.3−58.4%100% | 17−42.2%100% | 30r30−23.5%100% | 39—100% | — | |
| Accounts payable | 1.0−12.7%12.4% | 1.1−4.4%11.6% | 1.1+9.4%7.3% | 1.0−30.1%14.4% | 1.5−1.5%8.6% | 1.5r1.2+34.3%5.1% | 1.1—2.9% | — | |
| Current liabilities | 1.8+9.0%24.0% | 1.7−23.8%17.9% | 2.2−16.0%14.2% | 2.6−28.3%36.4% | 3.7+2.1%21.2% | 3.6r3.3−47.9%12.0% | 6.9—17.6% | — | |
| Total liabilities | 3.0+68.4%39.0% | 1.8−22.8%18.8% | 2.3−12.6%14.8% | 2.6−28.3%36.4% | 3.7+2.1%21.2% | 3.6r3.3−48.5%12.0% | 7.0—17.8% | — | |
| Retained earnings | −291—−3771% | −285—−3010% | −278—−1783% | −276—−3802% | −266—−1525% | −252—−835% | −244—−619% | — | |
| Shareholders' equity | 4.7−38.7%61.0% | 7.7−42.2%81.2% | 13+188%85.2% | 4.6−66.5%63.6% | 14−48.2%78.8% | 27−18.1%88.0% | 32+325%82.2% | 7.6—— | |
| Total liabilities and equity | 7.7−18.6%100% | 9.5−39.4%100% | 16+115%100% | 7.3−58.4%100% | 17−42.2%100% | 30r30−23.5%100% | 39—100% | — | |
| Shares outstanding | 2.3r0.0+131650%— | 0.0r17−100.0%— | 17r17+26.3%— | 14r14+5.6%— | 13−0.1%— | 13r13+0.4%— | 13—— | — | |
| Cash-flow statement | |||||||||
| Depreciation and amortization | 0.1−7.2%17.6% | 0.1−55.9%11.0% | 0.2+26.4%3.6% | 0.2−28.1%4.7% | 0.2+3.4%2.6% | 0.2−1.7%1.3% | 0.2−77.5%1.4% | 1.1—7.6% | |
| Share-based compensation | 0.8−15.4%153% | 0.9+68.4%104% | 0.5−37.7%9.1% | 0.9−31.2%23.9% | 1.3−21.3%13.7% | 1.6−13.3%9.2% | 1.9+9.8%11.4% | 1.7—12.3% | |
| Cash from operating activities | −6.0—−1171% | −5.9—−671% | −2.0—−33.6% | −9.3—−253% | −11—−116% | −8.5r−8.4—−47.8% | −11—−64.9% | −17—−122% | |
| Capital expenditure | −0.0—−3.7% | −0.1—−11.3% | −0.0—−0.7% | −0.4—−10.2% | −0.4—−3.8% | −0.2—−1.0% | −0.3—−1.8% | −0.2—−1.3% | |
| Cash from investing activities | −1.9−137%−364% | 5.0—566% | −5.9−157%−98.0% | 10−3.9%283% | 11—116% | −22r−23—−127% | −0.3−110%−1.8% | 2.8—20.4% | |
| Debt repaid | — | — | — | — | — | — | — | −0.5—−3.3% | |
| Shares issued | 4.5—879% | −0.0−100%−2.7% | 11—177% | — | — | — | — | — | |
| Cash from financing activities | 4.5—879% | −0.0−100%−2.7% | 11—177% | 0—0.0% | 0−100%0.0% | 0.0−99.9%0.2% | 35+228%213% | 11—77.3% | |
| Change in cash | −3.3—−655% | −1.0−135%−108% | 2.7+147%45.0% | 1.1+2953%29.8% | 0.0—0.4% | −31−228%−174% | 24—146% | −3.4—−24.7% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Mar 31, 2017 | Q1 FY2017to Mar 31, 2017 | Q4 FY2016to Dec 31, 2016 | Q3 FY2016to Sep 30, 2016 | Q2 FY2016to Jun 30, 2016 | Q1 FY2016to Mar 31, 2016 | Q4 FY2015to Dec 31, 2015 | Q3 FY2015to Sep 30, 2015 | Q2 FY2015to Jun 30, 2015 | Q1 FY2015to Mar 31, 2015 | Q4 FY2014to Dec 31, 2014 | Q3 FY2014to Sep 30, 2014 | Q2 FY2014to Jun 30, 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 0.3−56.5%100% | 0.1−60.7%100% | 0.0−86.3%100% | 0.2−10.4%100% | 0.0−79.5%100% | 0.3−28.4%100% | 0.2−95.5%100% | 0.2−23.4%100% | 0.1−1.6%100% | 0.4—100% | 3.5—100% | 0.3—100% | 0.1—100% | |
| Research and development | 2.5−4.2%755% | 0.8+4.1%673% | 0.7*+28.5%3055% | 0.5−26.0%302% | 0.6−15.9%2185% | 0.7+13.7%254% | 0.5*−7.1%327% | 0.7+34.8%365% | 0.7+40.6%531% | 0.6—160% | 0.6*—16.0% | 0.5—208% | 0.5—372% | |
| General and administrative | 6.5+28.9%1931% | 2.7+88.0%2328% | 1.5*+14.0%6645% | 1.2+18.2%683% | 1.2−11.7%4508% | 1.4+9.2%487% | 1.3*+1.9%801% | 1.0−25.1%518% | 1.3+0.2%1045% | 1.3—319% | 1.3*—35.6% | 1.3—529% | 1.3—1027% | |
| Operating expenses | 9.0+17.5%2686% | 3.4+59.2%3001% | 2.1*+18.2%9700% | 1.7−0.1%984% | 1.7−13.1%6692% | 2.1+10.7%741% | 1.8*−0.9%1128% | 1.7−8.2%883% | 2.0+10.9%1576% | 1.9—479% | 1.8*—51.6% | 1.9—737% | 1.8—1399% | |
| Operating income | −8.7—−2586% | −3.3—−2901% | −2.1—−9595% | −1.5—−884% | −1.7—−6592% | −1.9—−641% | −1.6−196%−1028% | −1.5—−783% | −1.9—−1476% | −1.5—−379% | 1.7—48.4% | −1.6—−637% | −1.7—−1299% | |
| Other non-operating income (expense) | 0.5+3207%138% | −1.0—−847% | 0.6*+19467%2668% | 0.3+5283%187% | 0.5+8550%1996% | −0.0—−0.3% | 0.0*—1.9% | 0.0—3.1% | 0.0—4.7% | — | — | — | — | |
| Net income attributable to shareholders | −8.2—−2448% | −4.3—−3748% | −1.5—−6932% | −1.2—−698% | −1.2—−4596% | −1.9—−641% | −1.6−196%−1026% | −1.5—−780% | −1.9—−1472% | −1.5—−378% | 1.7—48.6% | −1.6—−633% | −1.7—−1296% | |
| Earnings per share, basic | -3.67—— | -1.88—— | -0.67—— | -0.53r-0.05—— | -0.59r-0.06—— | -1.08r-0.11—— | -1.00r-0.10−1009%— | -0.90r0.09—— | -1.10r0.11—— | -0.90r0.09—— | 0.11—— | -0.10r0.10—— | -0.10r0.10—— | |
| Earnings per share, diluted | -3.67—— | -1.88—— | -0.67—— | -0.53r-0.05—— | -0.59r-0.06—— | -1.08r-0.11—— | -1.00r-0.10−1009%— | -0.90r0.09—— | -1.10r0.11—— | -0.90r0.09—— | 0.11—— | -0.10r0.10—— | -0.10r0.10—— | |
| Shares, weighted average (diluted) | 2.3+31.7%— | 2.3+31.7%— | — | 23+35.7%— | 20+23.2%— | 1.7r0.0+10335%— | — | 17+1.3%— | 17r0.0+99900%— | 0.0r17—— | — | 17—— | 0.0r17—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 2.5—51.7% | 2.5−60.0%51.7% | 3.7−47.7%47.6% | 4.9−25.6%52.8% | 9.6+43.8%91.5% | 6.3−11.4%82.8% | 7.0−12.0%74.1% | 6.6+63.0%60.6% | 6.7+31.8%55.0% | 7.2—52.3% | 8.0—51.0% | 4.0—29.3% | 5.1—32.5% | |
| Receivables | 0.1—1.7% | 0.1−40.0%1.7% | 0.0−86.7%0.3% | 0.2−33.1%1.9% | 0.0−82.6%0.5% | 0.1−67.2%1.8% | 0.2−48.9%1.8% | 0.3−18.1%2.4% | 0.3+76.7%2.3% | 0.4—3.1% | 0.3—2.1% | 0.3—2.3% | 0.2—1.0% | |
| Other current assets | 0.2—4.6% | 0.2−10.0%4.6% | 0.3+10.6%3.5% | 0.4+8.8%4.0% | 0.5+14.1%4.9% | 0.2+2.0%3.3% | 0.2+11.9%2.6% | 0.3+15.7%3.1% | 0.5+14.6%3.7% | 0.2—1.8% | 0.2—1.4% | 0.3—2.1% | 0.4—2.5% | |
| Current assets | 4.6—93.6% | 4.6−37.1%93.6% | 7.5−17.9%96.8% | 8.9−14.9%96.5% | 10−13.8%96.9% | 7.3−45.3%95.4% | 9.1−40.4%96.0% | 11−21.4%96.8% | 12−21.8%97.0% | 13—97.4% | 15—97.6% | 13—97.2% | 15—96.8% | |
| Property, plant and equipment | 0.3—5.2% | 0.3+0.8%5.2% | 0.2−31.5%2.5% | 0.2−7.3%2.5% | 0.2−12.8%2.2% | 0.30.0%3.3% | 0.3+1.1%2.9% | 0.2−15.6%2.3% | 0.3−33.9%2.2% | 0.3—1.8% | 0.3—1.8% | 0.3—2.1% | 0.4—2.6% | |
| Total assets | 4.9—100% | 4.9−35.8%100% | 7.7−18.6%100% | 9.3−14.6%100% | 11−13.6%100% | 7.6−44.1%100% | 9.5−39.4%100% | 11−21.1%100% | 12−22.0%100% | 14—100% | 16—100% | 14—100% | 16—100% | |
| Accounts payable | 1.6—33.3% | 1.6+44.1%33.3% | 1.0−12.7%12.4% | 1.0+3.1%10.4% | 0.9+2.7%8.4% | 1.1+23.9%14.8% | 1.1−4.4%11.6% | 0.9+14.8%8.6% | 0.9−21.5%7.1% | 0.9—6.7% | 1.1—7.3% | 0.8—5.9% | 1.1—7.1% | |
| Current liabilities | 2.2—44.7% | 2.2+43.1%44.7% | 1.8+9.0%24.0% | 1.5−11.9%16.1% | 1.4−21.5%13.4% | 1.5−4.9%20.1% | 1.7−23.8%17.9% | 1.7−24.4%15.6% | 1.8−33.4%14.7% | 1.6—11.8% | 2.2—14.2% | 2.2—16.3% | 2.7—17.2% | |
| Total liabilities | 4.3—88.1% | 4.3+167%88.1% | 3.0+68.4%39.0% | 3.2+80.7%34.8% | 3.4+82.2%32.7% | 1.6−5.2%21.2% | 1.8−22.8%18.8% | 1.8−23.0%16.4% | 1.9−31.3%15.5% | 1.7—12.5% | 2.3—14.8% | 2.3—16.8% | 2.7—17.6% | |
| Retained earnings | −295—−6011% | −295—−6011% | −291—−3771% | −289—−3119% | −288—−2735% | −287—−3749% | −285—−3010% | −283—−2610% | −282—−2311% | −280—−2046% | −278—−1783% | −280—−2035% | −278—−1782% | |
| Shareholders' equity | 0.6—11.9% | 0.6−90.3%11.9% | 4.7−38.7%61.0% | 6.0−33.3%65.2% | 7.1−31.2%67.3% | 6.0−49.7%78.8% | 7.7−42.2%81.2% | 9.1−20.7%83.6% | 10−20.0%84.5% | 12—87.5% | 13—85.2% | 11—83.2% | 13—82.4% | |
| Total liabilities and equity | 4.9—100% | 4.9−35.8%100% | 7.7−18.6%100% | 9.3−14.6%100% | 11−13.6%100% | 7.6−44.1%100% | 9.5−39.4%100% | 11−21.1%100% | 12−22.0%100% | 14—100% | 16—100% | 14—100% | 16—100% | |
| Shares outstanding | 2.3—— | 2.3−86.8%— | 2.3r0.0+131650%— | 23+31.7%— | 23+131550%— | 17−0.0%— | 0.0r17−100.0%— | 17−0.0%— | 0.0−99.9%— | 17—— | 17r17—— | 17—— | 17—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.1−13.0%26.0% | 0.0−11.5%20.2% | 0.0*−20.0%90.9% | 0.0*−12.0%12.7% | 0.0*−8.3%84.6% | 0.0+13.0%9.0% | 0.0*+8.7%15.6% | 0.0*−62.7%13.0% | 0.0*−20.0%18.9% | 0.0—5.7% | 0.0*—0.7% | 0.1*—26.6% | 0.0*—23.3% | |
| Share-based compensation | 0.7−21.8%217% | 0.1−26.2%131% | 0.2*−16.5%850% | 0.2*−31.4%116% | 0.2*−9.9%735% | 0.2+4.1%69.7% | 0.2*+40.0%140% | 0.3*+79.8%152% | 0.2*+66.9%167% | 0.2—47.9% | 0.2*—4.5% | 0.2*—64.7% | 0.1*—98.4% | |
| Cash from operating activities | −7.0—−2093% | −2.8—−2454% | −1.2*—−5600% | −1.2*—−680% | −1.8*—−6942% | −1.8—−610% | −1.2*−162%−764% | −1.2*—−599% | −1.5*—−1195% | −2.0—−504% | 2.0*—55.6% | −1.8*—−720% | −0.6*—−447% | |
| Capital expenditure | — | −0.1—−76.3% | — | — | — | — | −0.1*—−35.0% | −0.0*—−4.1% | — | — | −0.0*—−0.1% | 0*—0.0% | −0.0*—−3.9% | |
| Cash from investing activities | −1.3−126%−382% | 1.7+53.3%1461% | 0.0*−99.6%31.8% | −3.5*−436%−2038% | 0.6*−46.6%2208% | 1.1−11.2%375% | 1.7*−16.1%1039% | 1.0*+35.9%544% | 1.1*—846% | 1.2—302% | 2.0*—56.1% | 0.8*—306% | −9.4*—−7320% | |
| Shares issued | — | — | 0*—0.0% | −0.0*—−20.2% | — | — | −0.0*—−2.5% | −0.0*—−6.2% | — | — | −0.0*—−0.2% | −0.0*—−1.6% | −0.1*—−69.0% | |
| Cash from financing activities | — | — | — | −0.0*—−20.2% | — | — | −0.0*—−2.5% | −0.0*—−6.2% | — | — | −0.0*—−0.2% | −0.0*—−1.6% | −0.1*—−69.0% | |
| Change in cash | −3.8—−1133% | −1.1—−992% | −1.2*−381%−5568% | −4.7*—−2739% | 3.3*—12681% | −0.7—−235% | 0.4*−88.9%273% | −0.1*—−62.2% | −0.5*—−355% | −0.8—−202% | 3.9*—111% | −1.0*—−415% | −10*—−7836% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Mar 31, 2017. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at GenVec#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Delisting notice 3 · Auditor changed 1 · Taken over and delisted 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 4 · Material agreement 2 · Unregistered share sale 1 · Shareholder rights changed 2 · Bylaws or fiscal year changed 3 · Shareholder vote 4 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Taken over and delistedChange in controlAcquisition or sale completedDirectors and officersShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Material agreementShareholder rights changed | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Jun 16, 2017
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2010 | $2 M | No. 1 | $2 to $10 million | 1 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2013 | · | · | · | · | · | 41 | · | · | · | · | · | · | 41 |
| 2012 | · | · | · | · | · | · | · | · | 23 | · | · | · | 23 |
| 2009 | 22 | · | · | · | · | · | · | · | · | · | · | · | 22 |
| 2006 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 41 people | Restructuring planSEC 8-K | “(the “Company”) announced that it is terminating the employment of 30 of its remaining 41 employees.” | Filing | |
| 23 people (30% of workforce) | Restructuring planSEC 8-K | “(the “Company”) announced that it is lowering its operating costs to conserve capital, including eliminating 23 positions, or approximately 30% of its workforce.” | Filing | |
| 22 people | Restructuring planSEC 8-K | “On January 29, 2009, GenVec, Inc. announced that it is lowering its operating costs in order to increase the Company’s efficiency, including eliminating 22 positions.” | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How GenVec compares in Biotechnology
- Revenue$1 M · higher than 21% of 647
- Revenue growth-42.0% · higher than 22% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| GenVec🇺🇸 | — | — | — | -42.0% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Annual results:
- For year ending December-2016
- Balance sheet:
- As of December-2016
- Employees:
- As of February 28, 2017
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, Wikidata, SEC annual report, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at GenVec? Verify and update this profile — free
Show GenVec's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.